🔎 Trials Near Me

Home › Brain Tumors › NCT04427384

Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)

RecruitingObservational study

A Multicenter Observational Study of GammaTile™ Surgically Targeted Radiation Therapy (STaRT) in Intracranial Brain Neoplasms

Who can join

All ages · All sexes

Full eligibility criteria
Inclusion Criteria:

1. Patients who undergo maximum safe resection of intracranial neoplasm(s) AND implantation of GammaTiles.
2. Willing and able to provide informed consent and to participate in all evaluations.

Exclusion Criteria:

1. Inability to undergo pre-operative and post-operative imaging for disease and implant assessment.
2. Major medical or psychiatric illness, which, in the investigator's opinion would prevent completion of treatment, ability to complete assessments at the time of enrollment, and/or interfere with follow ups.
3. Subjects who, in the investigator's opinion, are unable to understand the protocol or to give informed consent, have a history of poor cooperation, noncompliance with medical treatment, or difficulty in returning for follow up care. A legally authorized representative may provide consent if the potential subject lacks the capacity to provide consent themselves.

About the study

The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.

What is being tested

Sponsor: GT Medical Technologies, Inc. · Participants: 600 · Started: Sep 11, 2020

Contact the study team

Official record on ClinicalTrials.gov — NCT04427384

Locations in the U.S.

ArizonaHonorHeath Scottsdale Osborn Medical Center, Phoenix
ArkansasUniversity of Arkansas Medical Center, Little Rock
CaliforniaEden Medical Center, Castro Valley
UCSD Moores Cancer Center, La Jolla
MemorialCare Health System, Laguna Hills
Desert Regional Medical Center, Palm Springs
California Pacific Medical Center, Sutter health, San Francisco
ColoradoCentura, Denver (Not yet recruiting)
Colorado Brain & Spine Institute: Swedish Campus, Englewood
FloridaBayCare Health, Clearwater
Ascension St. Vincent's, Jacksonville
Miami Cancer Institute, Baptist Health South Florida, Miami
Advent Health Orlando, Orlando
Orlando Health, Orlando
Florida Health Sciences Center, Inc. d/b/a Tampa General Hospital, Tampa
Cleveland Clinic Florida- Weston, Weston
GeorgiaPiedmont Healthcare, Atlanta
Winship Cancer Institute of Emory University, Atlanta
IdahoSt. Alphonsus Regional Medical Center, Boise
IndianaGoodman Campbell Brain and Spine, Carmel
Indiana University, IU Health Methodist Hospital, Indianapolis
KansasKUMC Dept of Neurosurgery, Kansas City
KentuckyNorton Cancer Institute, Louisville
Univeristy of Louisville Health, Louisville
MassachusettsBeth Israel Deaconess Medical Center, Boston
Beth Israel Deaconess Medical Center, Boston
MichiganHenry Ford Health System, Detroit
MinnesotaAbbott Northwestern Hospital, Minneapolis
University of Minnesota, Minneapolis
NebraskaUniversity of Nebraska, Omaha
New JerseyClinical Research dep. Davison Place. Englewood Health, Englewood (Not yet recruiting)
New YorkAlbany Medical Center, Albany
SUNY Upstate Medical Center, Syracuse
Montefiore Einstein, The Bronx
Westchester Medical Center, Valhalla
North CarolinaVidant Heath - ECU Medical Center, Greenville
Atlantic Brain & Spine, Wilmington
OhioMayfield Brain and Spine, Cincinnati
Kettering Health, Kettering
PennsylvaniaSt Luke's University Health, Sacred Heart Campus, Allentown
Penn State Health, Hershey
Allegheny Health Network, Pittsburgh
Rhode IslandBrown University Health, Providence
TennesseeCHI Memorial Hospital, CommonSpirit, Chattanooga
TexasUT Southwestern Simmons Cancer Center, Dallas
Baylor St. Luke's Medical Center | Baylor College of Medicine, Houston
Houston Methodist Hospital, Houston
University of Texas Health Science Center of San Antonio, San Antonio
Texas Oncology-The Woodlands, The Woodlands
VirginiaINOVA Health, Fairfax
WashingtonVirginia Mason, Seattle

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.